


PHARMACEUTICAL 2017



ALPINE IMMUNE SCIENCES INC. Rank 161 of 313





PHARMACEUTICAL 2017



ALPINE IMMUNE SCIENCES INC. Rank 161 of 313

The relative strengths and weaknesses of ALPINE IMMUNE SCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALPINE IMMUNE SCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 364% points. The greatest weakness of ALPINE IMMUNE SCIENCES INC. is the variable Research and Development, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -195%, being 221% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	61,663
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,499
Liabilities, Non-Current	0
Other Assets	272
Other Compr. Net Income	-20
Other Expenses	0
Other Liabilities	0
Other Net Income	439
Property and Equipment	0
Research and Development	23,316
Revenues	0
Selling, General and Administrative Expense	8,586

Output Variable	Value in 1000 USD
Assets	61,935
Liabilities	6,499
Expenses	31,902
Stockholders Equity	55,436
Net Income	-31,463
Comprehensive Net Income	-31,473
Economic Capital Ratio	-195%